INTRODUCTION
Primary Localized Cutaneous Amyloidosis (P.L.C.A) is a rare condition in which deposition of amyloid occurs in apparently normal skin with no deposition in internal organs. Amyloid is extracellular proteinaceous accumulation which is resistant to proteolytic digestion.
1,2 The etiology is not known, but some suggest that frictional trauma to the epidermis causes necrosis of keratinocytes and formation of amyloid in the papillary dermis.
1,2,3 P.L.C.A may be associated with autoimmune disorders. 4 P.L.C.A is reported in China, India & South America. Incidence in Saudi Arabia is 0.15% and in India is 0.27%. 5, 6, 7 Another study in India shows incidence of lichen amyloidosis to be 65.63%. 2 Most cases are sporadic but 10% are Autosomal dominant. Although Oncostatin M Receptor (OSMR) gene and IL3IRA mutations has been reported. 1, 6, 8 P.L.C.A consists of macular and lichen amyloidosis, and sometimes both forms may co-exist. Rare forms are bullous, vitiliginous or ichthyosiform amyloidosis. 1, 2, 9 Clinically Lichen amyloidosis (L.A) presents as closely set, discrete, brownred hyperkeratotic papules or plaques with slight scaling which are intensely itchy, located more commonly on the trunk or extremities especially the shins. 11 and 90% (daily use of D.M.S.O 50%). 13 These studies were done in 1997 and 1998, and no study was conducted after that. Data on our population is not available, therefore the present study is designed to assess the efficacy of D.M.S.O 70% and if found to be higher, then it will be utilized in future for such cases.
MATERIAL & METHODS Study Design Case series

Settings
This study was conducted at dermatology department, Abbasi Shaheed Hospital in outpatient department (OPD).
Duration of Study
The data collection was done in 06 months after approval of synopsis. 
Sample Size
Sample size of 71 adult subjects meeting inclusion criteria was required for this study, on the basis of previous study by Ozkaya. 13 With efficacy of 90%, confidence interval 95%, and 7% precision using computer program "OpenEpi version 2" for calculation of sample size. http://www.openepi.com/samplesize/SSpropor. htm
Sampling Technique
Non probability consecutive sampling. 
SAMPLE SELECTION
Inclusion Criteria
Data Collection Procedures
After approval from ethical committee of hospital, the study was conducted in Dermatology O.P.D, Abbasi Shaheed Hospital, 71 patients meeting the inclusion criteria were included after taking an informed consent. A detailed history regarding the duration of illness, papules or plaques, itching sites involved were taken. Pruritis as subjective symptoms were graded by patient individually on a 10 cm visual analog scale (0-10), 0 being absent and 10 means maximum itching. Patients were advised to apply a thin layer on affected area twice daily, 70% D.M.S.O in aqueous base available by name of Amyloidosis cream (Merck marker Private Limited cat no:802912 synthetic grades, formulated by Nigehban pharmacy). Presence of papules was observed clinically and 3 after 3 months of topical application of D.M.S.O lesions were assessed again for absence or presence of papules. Disappearance of papules and no to mild pruritis was considered as efficacy positive
OPERATIONAL DEFINITIONS Lichen Amyloidosis
Presence of pruritic eruption of multiple discrete hyperkeratotic papules, predominantly on the anterior leg, upper back, forearms and thigh was considered as Lichen Amyloidosis.
Papule
A solid rounded growth that is raised from the skin and was less than 1 cm (0.5 inches) across. It was diagnosed clinically.
Plaque
A well-circumscribed, raised, superficial, solid lesion, greater than 1 cm in diameter, usually "plateau-like" with a flat top was considered a plaque.
Pruritis
The subjective sensation of lesional itch was considered as pruritis positive. As it was a subjective symptom it was graded by patient individually on a 10 cm visual analog scale (VAS) (0-10), 0 being absent, mild 1-3, moderate 4-7, severe 8-10.
Efficacy
Disappearance of papules and no to mild pruritis was considered as efficacy positive, at the end of three months. 13 We planned this study considering the fact that the studies are done in 1997 and 1998, and no study was conducted after that. Data on our population is not available, therefore we assessed the efficacy of D.M.S.O 70% in our study and on the basis of higher efficacy it may be utilized in future for such cases. to studies done by Djuanda et al. and Looi. 14, 15 The age of onset of the disease was also 30 -50 years, and the patients seemed to report within a short period of onset of the disease. The disease seemed to be more prevalent among the married and patients belonging to the lower class. Age could act as a confounder in the association found between marriage and cutaneous amyloidosis.
RESULTS
Our findings are in accordance with the above studies, we computed the common age in our patients as 41.79+10.87 years.
Our results are comparable with two studies by the same researchers done at Turkey showing the efficacy of 72% (intermittent use of D.M.S.O 50%) 11 and 90% (daily use of D.M.S.O 50%).
13
A recent trial 16 evaluated the effect of dimethylsulphoxide on cutaneous amyloidosis and recorded its effect on pruritus, pigmentation, and papules was excellent in the initial one month (P value < 0.0001). Thereafter, the symptoms improved, but not as significantly as compared to the previous month.
Pandhi R et al. observed a decrease in pruritus score, but not a complete disappearance in any of the patients treated with 100% DMSO after 12 weeks of treatment. Also, complete remission of pigmentation was observed in only 24% of the patients and flattening of papules in only 16.6% of the cases. 17 The studies are very limited recording the efficacy of DMSO for the management of lichen amyloidosis, however, our findings are in accordance with the above studies and on the basis of its higher efficacy it may be utilized in future for such cases. Copyright© 15 May, 2017.
